Physician profile
Jeffrey C Haskell
NPI 1073535506
$5,360.39
in general payments reported to CMS, 2019-2025
32 companies · $531 in 2025
The $531 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,055 · 2020: $41.16 · 2021: $345 · 2022: $553 · 2023: $181 · 2024: $653 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,365.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $1,926.50 | 2019 | |
| Abbvie INC. | $1,264.88 | 2021-2025 | |
| Active Medical, LLC | $1,128.94 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $165.06 | 2022-2024 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $64.57 | 2022 | |
| Vanda Pharmaceuticals INC. | $56.66 | 2024-2025 | Fanapt |
| Axsome Therapeutics, INC. | $53.06 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $48.85 | 2022 | |
| Novo Nordisk INC | $48.60 | 2023-2025 | Rybelsus, Ozempic |
| Alkermes, INC. | $48.38 | 2025 | Vivitrol |
| Xeris Pharmaceuticals, INC. | $44.19 | 2024-2025 | Gvoke Hypopen |
| Boston Scientific Corporation | $42.18 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $41.24 | 2020-2021 | |
| Itamar Medical INC | $36.19 | 2023 | Watchpatone |
| Jazz Pharmaceuticals INC. | $34.28 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $34.07 | 2025 | Airsupra, Farxiga |
| Daiichi Sankyo INC. | $33.20 | 2025 | Injectafer |
| Inspire Medical Systems, INC. | $28.75 | 2025 | Inspire |
| Ferring Pharmaceuticals INC. | $27.80 | 2025 | Adstiladrin |
| Allergan, INC. | $26.47 | 2020 | |
| Biodelivery Sciences International, INC. | $25.68 | 2021 | |
| Therapeuticsmd, INC. | $20.66 | 2022 | |
| Shield Therapeutics INC | $18.95 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $17.51 | 2023 | Rexulti |
| Lilly USA, LLC | $17.16 | 2024 | Zepbound |
| Pfizer INC. | $17.06 | 2023 | |
| Mylan Specialty L.P. | $15.64 | 2024 | Yupelri |
| Harmony Biosciences LLC | $15.56 | 2024 | |
| Phathom Pharmaceuticals, INC. | $15.53 | 2024 | Voquezna |
| Exact Sciences Corporation | $15.09 | 2024 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $14.16 | 2023 | Ultomiris |
| Viatris Specialty LLC | $13.52 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Haskell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.